Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 4

Exploring Toxicities for Second Line Treatments in mCRC

, , , ,

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    Now Viewing
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Briefly discuss common AEs for patients treated with 2L biomarker-directed therapy for mCRC.
      • What similarities and differences can be observed based on specific clinically actionable targets?
      • What strategies have you explored to mitigate and manage those events?
    2. Dr Marshall: Based on the following data updates presented in mCRC, how does this impact the future treatment landscape in the second line setting?

    x